The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

100 patients will be randomly assigned to receive either TACE alone or TACE plus LMWH. A block of every 4 participants and a stratified randomization according to portal vein cancer emboli will be used to restrict randomization. LMWH consisted of nadroparin Ca will be given at a dose of 4100 U twice daily during 6 weeks after TACE. The time to progression(TTP) and overall survival within two years will be used to evaluate the effect of LMWH on HCC.

Inclusion criteria

• Adults patients with a diagnosis of HCC which is not amenable to surgical resection, liver transplantation or local ablative therapy
• Without metastasis out of liver
• Patients must have at least one tumor lesion that meets both of the following criteria:

• The lesion can be accurately measured in at least one dimension according to RECIST criteria
• The lesion has not been previously treated with surgery, radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid injection, or cryoablation.
• ECOG performance status (PS) <2
• No prior targeted antiangiogenic therapy. Metronomic chemotherapies are allowed. At least 4 weeks since prior systemic chemotherapy
• Child-Pugh class A or B
• No significant renal impairment (creatinine clearance < 30 mL/minute) or patients on dialysis
• Ability to understand the protocol and to agree to and sign a written informed consent document -

Exclusion criteria

• HBSAg(-)，AFP(-).
• prothrombin time prolonged more than 4s.
• blood platelets count less than 50000/L.
• Renal failure requiring dialysis.
• Child-Pugh class C hepatic impairment.
• clinically significant gastrointestinal bleeding within 30 days prior to study entry.
• History of organ allograft.
• Substance abuse (current), psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
• Known or suspected allergy to the investigational agents or any agent given in association with this trial.
• Pregnant or breast-feeding patients.